Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

CGRP

Bayer symbol

Bayer and Merck take high-risk heart failure drug into phase III

Embarks on final study of vericiguat despite it not meeting objectives in phase II trial

- PMLiVE

Boehringer buys into oncolytic viruses via €210m ViraTherapeutics deal

Option to acquire the Austrian biotech after phase I trials remains open to Boehringer 

- PMLiVE

NICE backs Bayer’s Eylea as first-line BRVO treatment

Recommends visual impairment therapy over current laser treatment

Shire Basingstoke

Shire gives up on Momenta-partnered Humira biosimilar

Will fund programme for another 12 months while divesting ongoing activities to Momenta

- PMLiVE

Amgen’s Kyprolis scarred by head-to-head duel with Velcade

Failed to show superior progression-free survival in first-line treatment trials

- PMLiVE

Novartis’ Ilaris wins three new FDA approvals

Immunotherapeutic expands in rare Periodic Fever Syndrome conditions

- PMLiVE

Kite Pharma soars after positive CAR-T data in lymphoma

Looks to become first marketed CAR-T drug as phase II results pave way for US filing

- PMLiVE

Amgen claims first US go-ahead for Humira biosimilar

Amjevita receives FDA approval but faces patent infringement lawsuit from AbbVie

- PMLiVE

Chiesi’s Holoclar wins UK Prix Galien orphan drug award

Novartis and Astellas also scoop prizes at the prestigious ceremony

- PMLiVE

Novartis seeks first-line use for lung cancer drug Zykadia

Looks to go head-to-head with Pfizer/Merck KGaA’s Xalkori and Roche’s Alecensa

- PMLiVE

Merck decision to drop odanacatib lifts UCB/Amgen

Pulls plug on osteoporosis candidate after studies show high risk of stroke

- PMLiVE

Amgen agrees to take Cytokinetics’ heart failure drug into phase III

Phase II results showed significant cardiac function benefit and no adverse safety signals

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links